Are you Dr. Xu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 16 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
7301 College Blvd
Ste. 110
Overland Park, KS 66210Phone+1 913-341-6297Fax+1 913-341-6299
Summary
- Dr. Xiao Xu, MD is a board certified pathologist in Overland Park, Kansas. She is currently licensed to practice medicine in Kansas, Arizona, and Texas. She is affiliated with Overland Park Regional Medical Center.
Education & Training
- Rutgers Health/Robert Wood Johnson Medical SchoolResidency, Pathology-Anatomic and Clinical, 1995 - 1998
- Shanghai Medical UniversityClass of 1987
Certifications & Licensure
- AZ State Medical License 2019 - 2026
- CA State Medical License 2017 - 2024
- TX State Medical License 2019 - 2021
- KS State Medical License 2009 - 2020
- MO State Medical License 2010 - 2020
- American Board of Pathology Anatomic Pathology & Clinical Pathology
Publications & Presentations
PubMed
- 48 citationsSocioeconomic Stratification and Multidimensional Health Trajectories: Evidence of Convergence in Later Old AgeXiao Xu, Jersey Liang, Joan M. Bennett, Anda Botoseneanu, Heather G. Allore
The Journals of Gerontology. Series B, Psychological Sciences and Social Sciences. 2015-07-01 - 10 citationsEmergency Contraception Provision: A Survey of Michigan Physicians from Five Medical SpecialtiesXiao Xu, Anjel Vahratian, Divya A. Patel, Annie Laurie McRee, Scott B. Ransom
Journal of Women's Health. 2007-05-01 - 23 citationsThe effects of medical liability on obstetric care supply in MichiganXiao Xu, Kristine Siefert, Peter D. Jacobson, Jody R. Lori, Scott B. Ransom
American Journal of Obstetrics and Gynecology. 2008-02-01
Press Mentions
- Effects of ATP9A on Extracellular Vesicle Release and Exosomal Lipid CompositionOctober 29th, 2020
- Severity of Early Allograft Dysfunction Following Donation After Circulatory Death Liver Transplantation: A Multicentre StudyOctober 14th, 2019
- ACEA Biosciences Announces Successful Completion of Phase I Clinical Study of Novel Autoimmune Disease DrugJune 14th, 2017